serelaxin

This page shows the latest serelaxin news and features for those working in and with pharma, biotech and healthcare.

New drugs can't keep Novartis sales on the up

year. A decision to drop development of acute heart failure drug serelaxin (RLX030) also pegged back Novartis' profits, forcing the company to take a charge of $200m in the quarter.

Latest news

What future for serelaxin after phase III miss?

What future for serelaxin after phase III miss? Novartis' acute heart failure therapy misses two main endpoints. ... credibility". Novartis had been hoping to build a valuable heart failure franchise around serelaxin for AHF and Entresto (sacubitril and
Novartis boosts cardiovascular pipeline with $1bn Ionis deal

The company launched first-in-class chronic heart failure therapy Entresto (sacubitril and valsartan) in 2015 and is hoping to re-file acute heart failure candidate serelaxin (RLX030) this year.
Novartis says Cosentyx is 'outpacing competitors'

These include RLX030 (serelaxin) for acute heart failure, Fovista (pegpleranib) and RTH258 (brolucizumab) for neovascular age-related macular degeneration (AMD), and novel migraine prevention drug AMG334.
Novartis will file heart failure drug before year-end

Novartis was less successful in its efforts to secure approval of acute heart failure therapy Reasanz (serelaxin), which was rejected by an FDA advisory committee earlier this year because of a
CHMP turns down Avastin for brain cancer

heart failure drug Reasanz (serelaxin).

More from news
Approximately 11 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Heart failure therapy embarks on a new era

Other candidates in mid-stage testing include: natriuretic peptide receptor agonists from Capricor Therapeutics (cenderitide) and Palatin Technologies (PL-3994); Novartis' synthetic human relaxin 2 hormone serelaxin (knocked back by regulators
Interview: Elmar Schnee, Cardiorentis

It's a company with great potential, according to Schnee, who has high hopes for its lead drug candidate ularitide – an investigational product that is in competition with Novartis' serelaxin to ... Because of the serelaxin trial [by Novartis], you saw

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Senior Account Manager – Healthcare Advertising: Salary TBC

Account Director, Healthcare Advertising Agency: Salary TBC

Associate Scientific Director: Salary TBC

Sudler London - Account Director: Competitive

Senior Writer, Healthcare Advertising, London: Excellent package

Senior Medical Writer, MedComms Agency: Salary TBC

Account Director or Senior Account Director: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Healthcare PR Director: £100, 000 – £120, 000 benefits

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Market Access Consultant - Greater Manchester: Negotiable

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Healthcare PR Senior Account Manager: Salary TBC

Sudler London - Senior Medical Writer: Competitive

Systematic Review Lead- London: Negotiable

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Senior Training Manager - Surrey: Competitive Salary &Bonus

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Subscribe to our email news alerts

PMHub

Add my company

Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....